VEEV Stock Analysis: Veeva Systems | NYSE
Health Information Services | NYSE, USA | Market Cap: 30.741m USD | 12M Return: -36.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 340M
EPS Trend: 99.1%
Qual. Beats: 15
Rev. Trend: 99.9%
Qual. Beats: 10
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Veeva Systems Inc. (NYSE: VEEV) is a U.S.-based cloud software company that serves the global life sciences industry, including pharmaceutical, biotechnology, and consumer products companies. The companys offerings are organized into several cloud platforms: Commercial Cloud (covering CRM, medical content, digital asset management, and analytics), Data Cloud (customer reference data, patient data, and engagement metrics), Development Cloud (clinical trial execution, data management, safety, and regulatory information management), and Quality Cloud. Beyond software subscriptions, Veeva provides implementation, consulting, training, and managed services. Founded in 2007 as Verticals onDemand, it rebranded to Veeva Systems in April 2009, went public in October 2013, and is headquartered in Pleasanton, California. The company operates on a subscription-based SaaS model, which is the standard delivery approach for enterprise software, and its focus on regulated, compliance-heavy workflows (such as clinical trials and regulatory submissions) has made it a specialized vendor within the broader Health Care Technology sub-industry.
- Vault subscription revenue sustains double-digit growth into fiscal 2025
- Pharma R&D budget pressure weighs on Development Cloud bookings
- Data Cloud segment expands with Compass patient analytics adoption
| Net Income: 941.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 2.74 > 1.0 |
| NWC/Revenue: 191.7% < 20% (prev 183.9%; Δ 7.76% < -1%) |
| CFO/TA 0.18 > 3% & CFO 1.67b > Net Income 941.7m |
| Net Debt (-7.21b) to EBITDA (1.30b): -5.55 < 3 |
| Current Ratio: 4.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (166.0m) vs 12m ago -0.14% < -2% |
| Gross Margin: 74.95% > 18% (prev 75.50%; Δ -0.55% > 0.5%) |
| Asset Turnover: 39.29% > 50% (prev 36.77%; Δ 2.52% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.70 (Total Current Assets 8.06b - Total Current Liabilities 1.70b) / Total Assets 9.13b |
| B: 0.51 (Retained Earnings 4.62b / Total Assets 9.13b) |
| C: 0.15 (EBIT TTM 1.24b / Avg Total Assets 8.45b) |
| D: 4.00 (Book Value of Equity 7.30b / Total Liabilities 1.83b) |
| Altman-Z'' = 11.41 = AAA |
| DSRI: 1.00 (Receivables 627.8m/541.3m, Revenue 3.32b/2.86b) |
| GMI: 1.01 (GM 75.50% / 74.95%) |
| AQI: 0.83 (AQ_t 0.10 / AQ_t-1 0.12) |
| SGI: 1.16 (Revenue 3.32b / 2.86b) |
| TATA: -0.08 (NI 941.7m - CFO 1.67b) / TA 9.13b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of July 27, 2026, the stock is trading at USD 186.24 with a total of 821,572 shares traded. Over the past week, the price has changed by -4.68%, over one month by +8.68%, over three months by +16.07% and over the past year by -36.35%.
Current recommended Stop Loss: 168.70 (which is 9.4% or 2.3 ATR below the current price).
Veeva Systems has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy VEEV.
- StrongBuy: 12
- Buy: 7
- Hold: 11
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 244.6 | 31.3% |
P/E Trailing = 34.9797
P/E Forward = 21.9298
P/S = 9.2615
P/B = 4.3902
P/EG = 0.8903
Revenue TTM = 3.32b USD
EBIT TTM = 1.24b USD
EBITDA TTM = 1.30b USD
Long Term Debt = 89.9m USD (estimated: total debt 103.1m - short term 13.1m)
Short Term Debt = 13.1m USD (from shortTermDebt, last quarter)
Debt = 103.1m USD (from shortLongTermDebtTotal, last quarter) (leases 103.1m already included)
Net Debt = -7.21b USD (calculated: Debt 103.1m - CCE 7.31b)
Enterprise Value = 23.5b USD (30.7b + Debt 103.1m - CCE 7.31b)
Interest Coverage Ratio = unknown (Ebit TTM 1.24b / Interest Expense TTM 0.0)
EV/FCF = 14.32x (Enterprise Value 23.5b / FCF TTM 1.64b)
FCF Yield = 6.99% (FCF TTM 1.64b / Enterprise Value 23.5b)
FCF Margin = 49.52% (FCF TTM 1.64b / Revenue TTM 3.32b)
Net Margin = 28.37% (Net Income TTM 941.7m / Revenue TTM 3.32b)
Gross Margin = 74.95% ((Revenue TTM 3.32b - Cost of Revenue TTM 831.5m) / Revenue TTM)
Gross Margin QoQ = 74.71% (prev 74.46%)
Tobins Q-Ratio = 2.58 (Enterprise Value 23.5b / Total Assets 9.13b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 103.1m)
Taxrate = 24.26% (301.6m / 1.24b)
NOPAT = 941.7m (EBIT 1.24b * (1 - 24.26%))
Current Ratio = 4.74 (Total Current Assets 8.06b / Total Current Liabilities 1.70b)
Debt / Equity = 0.01 (Debt 103.1m / totalStockholderEquity, last quarter 7.30b)
Debt / EBITDA = -5.55 (Net Debt -7.21b / EBITDA 1.30b)
Debt / FCF = -4.39 (Net Debt -7.21b / FCF TTM 1.64b)
Total Stockholder Equity = 7.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.15% (Net Income 941.7m / Total Assets 9.13b)
RoE = 13.36% (Net Income TTM 941.7m / Total Stockholder Equity 7.05b)
RoCE = 17.41% (EBIT 1.24b / Capital Employed (Equity 7.05b + L.T.Debt 89.9m))
RoIC = 12.94% (NOPAT 941.7m / Invested Capital 7.27b)
WACC = 8.50% (E(30.7b)/V(30.8b) * Re(8.53%) + D(103.1m)/V(30.8b) * Rd(0.0%) * (1-Tc(0.24)))
Discount Rate = 8.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.43 | Cagr: 0.52%
[DCF] Terminal Value 77.48% ; FCFF base≈1.46b ; Y1≈1.67b ; Y5≈2.46b
[DCF] Fair Price = 266.7 (EV 36.1b - Net Debt -7.21b = Equity 43.3b / Shares 162.4m; r=8.50% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.13 | EPS CAGR: 27.82% | SUE: 1.88 | # QB: 15
Revenue Correlation: 99.95 | Revenue CAGR: 15.69% | SUE: 3.20 | # QB: 10
EPS current Quarter (2026-07-31): EPS=2.22 | Chg30d=+0.00% | Revisions=+67% | Analysts=24
EPS next Quarter (2026-10-31): EPS=2.29 | Chg30d=-0.00% | Revisions=+71% | Analysts=24
EPS current Year (2027-01-31): EPS=9.06 | Chg30d=+0.00% | Revisions=+89% | GrowthEPS=+11.9% | GrowthRev=+14.0%
EPS next Year (2028-01-31): EPS=10.03 | Chg30d=-0.00% | Revisions=+67% | GrowthEPS=+10.7% | GrowthRev=+12.1%
[Analyst] Revisions Ratio: +80% (up=86, down=8)